Tenecteplase no longer 'off label' for acute ischemic stroke
UC expert featured in MedCentral article
The University of Cincinnati's Yasmin Aziz was featured in a MedCentral article discussing the recent FDA approval of the drug tenecteplase (TNK) for treatment of acute ischemic stroke.
Trials of alteplase, also called tPA, were pioneered at the University of Cincinnati in the late 1980s, representing the first proven treatment for ischemic stroke. TNK is a more recently developed clot-busting drug that can be administered in a single IV injection within seconds.
Aziz said many academic health centers and private institutions have been using TNK off label since data from the 2022 ACT trial was published.
While there are new dosing instructions associated with the FDA approval, Aziz said the speed of delivering TNK makes it appealing. Administering tPA requires a 1-minute infusion followed by a 60-minute infusion of the rest of the dosage, while TNK requires a 5-second infusion.
“I will tell you, the ease of use is really what’s going to get people to change," said Aziz, MD, director, Acute Stroke Trials; associate director, Vascular Neurology Fellowship; and assistant professor in the Department of Neurology and Rehabilitation Medicine in UC's College of Medicine; UC Health neurologist; director, NIH StrokeNet Digital Media; and co-investigator, NIH StrokeNet Ohio Valley Regional Coordinating Center.
“I think this will hopefully allow us to treat more patients faster with less chance of error,” she continued. “It’s much easier to give a drug like tenecteplase in a moving ambulance."
Featured photo at top of illustration of brain with stroke symptoms. Photo/PeterSchreiber.media/iStock.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.